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background
 
New-generation, orally administered cholera vaccines offer the promise of improved
control of cholera in sub-Saharan Africa. However, the high prevalence of human im-
munodeficiency virus (HIV) infection in many cholera-affected African populations has
raised doubts about the level of protection possible with vaccination. We evaluated a
mass immunization program with recombinant cholera-toxin B subunit, killed whole-
cell (rBS-WC) oral cholera vaccine in Beira, Mozambique, a city where the seroprevalence
of HIV is 20 to 30 percent.
 
methods
 
From December 2003 to January 2004, we undertook mass immunization of nonpreg-
nant persons at least two years of age, using a two-dose regimen of rBS-WC vaccine in
Esturro, Beira (population 21,818). We then assessed vaccine protection in a case–con-
trol study during an outbreak of El Tor Ogawa cholera in Beira between January and
May 2004. To estimate the level of vaccine protection, antecedent rates of vaccination
were compared between persons with culture-confirmed cholera severe enough to have
prompted them to seek treatment and age- and sex-matched neighborhood controls
without treated diarrhea.
 
results
 
We assessed the effectiveness of the vaccine in 43 persons with cholera and 172 controls.
Receipt of one or more doses of rBS-WC vaccine was associated with 78 percent protec-
tion (95 percent confidence interval, 39 to 92 percent; P=0.004). The vaccine was equally
effective in children younger than five years of age and in older persons. A concurrently
conducted case–control study designed to detect bias compared persons with treated,
noncholeraic diarrhea and controls without diarrhea in the same population and found
no protection associated with receipt of the rBS-WC vaccine.
 
conclusions
 
The rBS-WC vaccine was highly effective against clinically significant cholera in an urban
sub-Saharan African population with a high prevalence of HIV infection.
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on February 19, 2014. For personal use only. No other uses without permission. 
 Copyright © 2005 Massachusetts Medical Society. All rights reserved. 
 n engl j med 
 
352;8
 
www.nejm.org february 
 
24
 
, 
 
2005
 
The
 
 new england journal 
 
of
 
 medicine
 
758
holera is endemic in mozambique,
 
with cases usually detected from January to
June during the rainy season. The cities of
Maputo and Beira are the worst affected. Despite
control strategies, including improved case man-
agement, water-chlorination campaigns, and dis-
semination of health-education messages, the bur-
den of cholera has remained high.
 
1
 
 As a result,
there is increasing interest in the use of cholera
vaccines.
New-generation, orally administered cholera
vaccines are promising tools for the control of chol-
era in these settings. One such vaccine, consisting
of recombinant cholera-toxin B subunit and killed
whole cells (rBS-WC), has been shown to confer
protection against endemic cholera and is interna-
tionally licensed.
 
2-5
 
 The World Health Organization
recently recommended that new-generation cholera
vaccines be considered in certain endemic and epi-
demic situations but indicated that demonstration
projects are needed to provide more information
about the costs, feasibility, and effects of using these
vaccines.
 
6
 
 Several uncertainties about these vac-
cines, including their protective effect in settings in
which the prevalence of human immunodeficiency
virus (HIV) infection is high, must be addressed
before they are introduced into public health pro-
grams.
To address the policy question of the feasibility
and effects of mass immunization with the rBS-WC
vaccine in Mozambique, we conducted a demon-
stration project in Beira, a city where cholera is en-
demic and the seroprevalence of HIV is high. We re-
port the results of a case–control study designed to
evaluate the protective effect of vaccination in this
setting.
 
study approval and informed consent
 
This project was approved by the government of
Mozambique; the institutional review board of the
International Vaccine Institute, Seoul, Korea; and
the Secretariat Committee on Research Involving
Human Subjects of the World Health Organization,
Geneva. Informed consent was obtained orally at
the community level through meetings with com-
munity leaders of Beira. Written informed consent
was obtained from all participants during the mass
vaccination and from all case subjects and controls
before their participation in the study.
 
vaccine
 
Each dose of the rBS-WC vaccine (Dukoral, SBL Vac-
cines) consists of 1 mg of recombinant cholera-tox-
in B subunit and approximately 1¬10
 
11
 
 inactivated
whole cells of the classic and El Tor biotypes of 
 
Vi-
brio cholerae
 
 O1, serotypes Inaba and Ogawa.
 
5
 
 This
vaccine and its predecessor (BS-WC), which con-
tained chemically extracted rather than recombi-
nant cholera-toxin B subunit, have been shown to
be safe and protective in several trials conducted in
settings where cholera is endemic,
 
2-5
 
 although none
of the trials were conducted in a setting with a high
prevalence of HIV infection.
The rBS-WC vaccine was supplied as 3-ml sin-
gle-dose vials, each with a sachet of sodium bicar-
bonate buffer. Buffer solution was prepared by dis-
solving the sachet in drinking water (150 ml of water
per sachet). The full dose of vaccine was mixed with
40, 75, or 150 ml of buffer solution for persons 2 to
4, 5 to 11, and more than 11 years of age, respective-
ly. The vaccine was refrigerated during shipping and
was stored centrally in a commercial cold-room fa-
cility in Beira. Cold boxes were used for transport
to the field.
 
study site and mass-immunization 
campaign
 
The port city of Beira, built on swampy ground at
the mouth of the Pungwe River, has a population of
approximately 450,000. Every year since 1998, Beira
has reported cases of cholera, and the disease is
considered to be endemic in the area.
 
1
 
 Periodic
flooding, difficult access to safe water, the common
practice of defecation in the open, the presence of
nonsealed latrines, and drainage of municipal waste
into the embankments increase the risk of cholera.
 
1
 
The government of Mozambique established the
Cholera Treatment Center in Beira to improve case
management and decrease case fatality rates.
 
1
 
 Oth-
er government treatment facilities in Beira (health
centers and the Central Hospital) routinely refer pa-
tients with acute, nonbloody diarrhea to the Cholera
Treatment Center. There are few private physicians,
and previous surveys have shown that traditional
healers are unlikely to be consulted for diarrheal
diseases. Thus, surveillance at the Cholera Treat-
ment Center detects nearly all of the city’s cases of
acute, nonbloody diarrhea requiring medical care.
Other than cholera, important public health prob-
lems in Beira are malaria, tuberculosis, HIV infec-
tion, and the acquired immunodeficiency syn-
c
methods
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drome. Sentinel surveillance for HIV infection
among pregnant women in Beira has shown a se-
ropositivity rate of 20 to 30 percent.
 
7
 
Residents of Esturro, a neighborhood in the
center of Beira with predominantly impoverished
residents, were selected as the target population for
immunization. A formal census in which the house-
hold address and the age and sex of each household
member were recorded was conducted from Sep-
tember to October 2003 and enumerated a total
population of 21,818 persons. All healthy, non-
pregnant residents of Esturro who were two years
of age or older were invited to participate in the
mass-vaccination campaign. During the census,
1177 residents (5.4 percent) were less than two years
of age, and an estimated 5.0 percent (or 1091 resi-
dents) were excluded because of potential pregnan-
cy, leaving a target population of 19,550 persons.
Before and throughout the mass immunization,
meetings with community leaders and a general in-
formation campaign were conducted. Since there
was substantial demand for vaccination, persons
from outside Esturro who requested the vaccine
were also immunized.
The mass vaccination was timed to take place be-
fore the anticipated yearly cholera outbreak, which
usually coincides with the rainy season. The vaccine
was administered in vaccination outposts set up
in churches and schools within Esturro. The first
round of immunization was conducted from De-
cember 11 to 20, 2003, and the second round from
January 5 to 12, 2004, thus ensuring a minimum of
15 days between doses.
To administer the vaccine, health care workers
shook the vial, opened it, and poured its contents
into a cup with buffer solution and stirred. The re-
cipient drank the mixture under direct observation,
and the completeness of ingestion was recorded.
No additional dose was given unless the contents
spilled before any amount had been ingested. Be-
cause the accuracy of information about the receipt
of vaccine was deemed to be crucial for the case–
control study of the effect of the vaccine, consider-
able effort was devoted to recording information
about dosing. During the first round, a card was is-
sued to each vaccine recipient to record his or her
name, age, and address; the name of the head of
his or her household; the date of vaccination; and
the completeness of ingestion of the dose. At the
time of dosing, this information was also recorded
in a vaccination registry. Only those persons who
had received a first dose (as documented on the vac-
cination card or in the registry) were given a second
dose of the vaccine during the second round of im-
munization.
 
postvaccination surveillance for cholera
 
Surveillance for acute, nonbloody diarrhea at the
Cholera Treatment Center began on January 1,
2004. An episode of acute diarrhea was defined as
the passage of three or more loose or liquid stools
over a 24-hour period, with an onset 14 or fewer
days before presentation. The date of onset of an
episode was defined as the day on which the diar-
rhea was reported to have begun.  Clinical informa-
tion was obtained for all patients and recorded on
case-report forms; dehydration was classified as
described elsewhere.
 
8
 
For surveillance, rectal swabs were collected
from all Esturro residents presenting to the Cholera
Treatment Center with acute, nonbloody diarrhea.
In addition, a rectal swab was collected daily from a
resident of a neighborhood other than Esturro who
was admitted to the Cholera Treatment Center with
acute, nonbloody diarrhea associated with severe
dehydration and whose illness was considered the
sentinel case in the Beira community. The rectal
swabs were transported every 12 hours in Cary-Blair
medium at room temperature to the study labora-
tory. From the Cary-Blair medium, the swabs were
plated directly onto thiosulfate citrate bile salts su-
crose agar and tellurite taurocholate gelatin agar.
 
9
 
The swabs were also plated after enrichment in al-
kaline peptone water (pH 8.6) for six hours at 37°C.
After overnight incubation at 37°C, suspected colo-
nies on the agar plates were tested biochemically
and agglutinated with polyvalent Ogawa and Inaba
antiserum (Difco Laboratories). Nonagglutinating
strains were tested with antiserum to 
 
V. cholerae
 
O139. 
 
V. cholerae
 
 strains were transported to the
Centre for Health and Population Research, in
Dhaka, Bangladesh, where identification of the iso-
lates was confirmed.
 
10
 
case–control studies
 
Two case–control studies were conducted concur-
rently: the first was designed to estimate the protec-
tive effect of the killed whole-cell oral cholera vac-
cine,
 
11
 
 and the second (a “bias-indicator study”)
was designed to assess whether the results with re-
spect to effectiveness could be attributed to bias.
 
12
 
The primary research question was as follows: Does
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receipt of one or more doses of the rBS-WC vaccine
provide protection against treated, culture-con-
firmed cholera? The case subjects and controls in
each of the two studies were the residents of Esturro.
In the first study, case subjects with cholera were
compared with controls who did not have diarrhea;
in the second, case subjects with noncholeraic diar-
rhea were compared with controls who did not have
diarrhea. Study staff who enrolled the case subjects
and controls and who obtained information on vac-
cination status and other exposure variables were
unaware that a separate, bias-indicator study was
being conducted and were also unaware of whether
 
V. cholerae
 
 O1 was cultured from the case subject and
of how the information on vaccination status was to
be used in the analysis. An absence of vaccine pro-
tection in the second study was to be interpreted as
suggesting an absence of bias in the first study.
 
Definition and Selection of Case Subjects
 
All patients with acute, nonbloody diarrhea severe
enough to cause them to seek care at the Cholera
Treatment Center between January 1 and May 31,
2004, were eligible to be included as case subjects
with cholera if they fulfilled the following criteria:
they gave written informed consent, or in the case
of minors, a parent or guardian gave written in-
formed consent for participation in the study; they
had resided in Esturro since December 11, 2003;
they were at least two years of age and were not preg-
nant during the time of the mass vaccination; they
submitted a fecal specimen that yielded 
 
V. cholerae
 
O1; and their residence could be located after dis-
charge for acquisition of information about vacci-
nation and other data. Repeated episodes meeting
the criteria during the selection interval were exclud-
ed. The interval from January 1 to May 31, 2004, was
chosen because all cases of cholera in 2004 occurred
during this period.
The bias-indicator study included all patients
presenting to the Cholera Treatment Center be-
tween April 1 and December 31, 2004, who met the
same selection criteria as those used for the case
subjects with cholera, except that their fecal cultures
were negative for 
 
V. cholerae
 
 O1. Since the rBS-WC
vaccine has been shown to provide cross-protection
against diarrhea due to heat-labile-toxin–produc-
ing 
 
Escherichia coli
 
 during a period of several months
after vaccination
 
13,14
 
 and since the goal of the bias-
indicator study was to assess whether there was an
expected absence of vaccine protection, we restrict-
ed case subjects in the bias-indicator study to those
presenting after April 1, 2004. A summary of the
participation of the two groups of case subjects is
shown in Figure 1.
 
Definition and Selection of Controls
 
A systematic selection procedure was used to re-
cruit four neighborhood controls for each case sub-
ject in the two studies.
 
15
 
 Starting from every third
house to the right of the case subject’s house, up to
six consecutive houses were visited until two eligi-
ble controls were enrolled. The procedure was then
repeated starting from every third house to the left
of the case subject’s house. Only one control was
recruited per household. A neighbor of the same
sex and within the same age group (2 to 4, 5 to 15,
or more than 15 years of age) as the case subject
was eligible to be a control if he or she had not
sought treatment for diarrhea at the Cholera Treat-
ment Center between December 11, 2003, and the
date of onset of the matched case subject’s diarrheal
illness and if he or she would have sought treat-
ment at the Cholera Treatment Center if severe, wa-
tery diarrhea had developed. Eligibility for selection
also required the same informed-consent, residen-
cy, age, and pregnancy criteria as those applied to
the case subjects. A neighbor who had been recruit-
ed to be a control for one case subject could not sub-
sequently be recruited to serve as a control for an-
other case subject. In the absence of a sex-matched
control for five case subjects in the two-to-four-year-
old age group, a control of the opposite sex as the
case subject was recruited. A summary of the partic-
ipation of controls is shown in Figure 1.
 
Ascertainment of Vaccination and Potentially
Confounding Variables
 
For the purpose of obtaining preselection informa-
tion about vaccination and other relevant variables,
the date of selection was defined as the date of en-
rollment of the case subject at the Cholera Treat-
ment Center, both for the case subject and his or her
matched controls. Receipt of the cholera vaccine
during the mass immunization program was ascer-
tained in face-to-face, home interviews of the case
subject and controls. Participants were asked wheth-
er they had been vaccinated and, if so, to show the
vaccination cards distributed during the campaign.
For those who reported that they had been vacci-
nated but were not in possession of a card, vaccina-
tion status and the completeness of dose ingestion
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were ascertained by searching the vaccination reg-
istry. Decisions about linkage to the vaccination reg-
istry were made without knowledge of case–control
status and were based on the participants’ name,
sex, age, and name of the head of the household.
Demographic, socioeconomic, and environmental
variables were ascertained through special ques-
tionnaires administered to case subjects and con-
trols and their families.
 
statistical analysis
 
The primary intention-to-vaccinate analysis, formu-
lated a priori, addressed the protection conferred by
one or more doses of vaccine against culture-con-
firmed cholera that was severe enough to have
prompted the participant to present for care at the
Cholera Treatment Center. This analysis included
case subjects with cholera and their matched con-
trols whose dates of selection were between Janu-
 
Figure 1. Summary of Participants in the Two Case–Control Studies, January 1 to December 31, 2004.
 
CTC denotes Cholera Treatment Center, Beira, Mozambique.
5777 Episodes of acute, nonbloody
diarrhea treated at the CTC
428 Episodes of acute, nonbloody
diarrhea among Esturro residents
5349 Episodes of acute, nonbloody
diarrhea among non–Esturro residents
248 Patients enrolled
47 Patients with culture-
confirmed cholera
201 Patients with diarrhea negative
on culture for Vibrio cholerae
14 Repeated episodes
12 Consent refused
122 Eligibility criteria not fulfilled
32 Missed by staff
141 Patients presented before
April 1, 2004
9 Households could not be
located
43 Case subjects with cholera included
in analysis of effectiveness
51 Case subjects included
in bias-indicator analysis
178 Potential controls approached
for analysis of effectiveness
210 Potential controls approached
for bias-indicator analysis
4 Households could not be
located
172 Controls enrolled 204 Controls enrolled
6 Potential controls ineligible 6 Potential controls ineligible
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ary 1 and May 31, 2004, with vaccination defined as
receipt of at least one dose, documented either by a
vaccination card or information in the vaccination
registry, regardless of the volume of vaccine suc-
cessfully ingested. For comparison, intention-to-
vaccinate analysis in the bias-indicator study ad-
dressed the protection conferred by one or more
doses of vaccine against noncholeraic diarrhea that
was severe enough to have prompted the participant
to present for care at the Cholera Treatment Center.
This analysis included case subjects with nonchol-
eraic diarrhea and their controls, with dates of se-
lection between April 1 and December 31, 2004.
In contrast, the per-protocol analysis addressed
the protection conferred by the receipt of two com-
pletely ingested doses of vaccine. Vaccinated case
subjects and controls were retained for this analysis
if their dates of selection were at least 14 days after
receipt of the second dose; nonvaccinated case sub-
jects and controls were retained if they had been se-
lected anytime between January 1 and May 31, 2004.
A per-protocol analysis was performed in the bias-
indicator study in an analogous fashion.
Demographic, environmental, and socioeco-
nomic variables were compared between case sub-
jects and their matched controls in bivariate analy-
ses with the use of conditional logistic regression.
Matched P values for associations between exposure
variables and case–control status were assessed in
these models, with case–control status as the de-
pendent variable and the exposure variable of inter-
est as the independent variable. For both case–con-
trol studies, all variables associated (at a significance
level of P<0.05) with case–control status in either
analysis were then adjusted for in conditional logis-
tic-regression models that also included vaccination
status as an independent variable and case–control
status as the dependent variable. The exponential of
the coefficient for the vaccination variable in these
models was computed to estimate the adjusted odds
ratio, and the standard error of the coefficient was
used to estimate the P value and 95 percent confi-
dence interval for this adjusted odds ratio. To esti-
mate the adjusted level of vaccine protection, the fol-
lowing value for the vaccination variable
 
11,15
 
 was
computed: (1¡adjusted odds ratio)¬100 percent.
A slightly different strategy was used in subgroup
analyses of vaccine protection. To avoid fitting the
conditional logistic-regression models with too
many independent variables for the number of out-
come events observed,
 
16
 
 small strata were analyzed
without control for potential confounding variables,
 
Figure 2. Episodes of Diarrhea and Cases of Cholera Treated at the Cholera Treatment Center, Beira, Mozambique, Janu-
ary 1 to May 31, 2004.
 
CTC denotes Cholera Treatment Center, Beira, Mozambique.
C
as
es
 o
f C
ho
le
ra
 o
r 
Ep
is
od
es
 o
f D
ia
rr
he
a 
am
on
g 
Es
tu
rr
o 
R
es
id
en
ts
Ep
is
od
es
 o
f D
ia
rr
he
a 
Tr
ea
te
d 
at
 th
e 
C
TC
70
60
40
30
10
50
20
0
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
Week of Surveillance
Episodes of diarrhea
treated at the CTC
80
400
350
250
200
100
50
300
150
0
450
Episodes of diarrhea
among Esturro residents
Cases of cholera
among Esturro residents
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on February 19, 2014. For personal use only. No other uses without permission. 
 Copyright © 2005 Massachusetts Medical Society. All rights reserved. 
 n engl j med 
 
352;8
 
www.nejm.org february 
 
24, 2005
 
effectiveness of mass oral cholera vaccination
 
763
 
and in larger strata, variables found to most affect
the magnitude of the odds ratio relating vaccination
to case–control status were included. On the basis
of previously published studies showing differenc-
es in protection according to the severity of disease
and age strata,
 
2,3
 
 case subjects were divided into
prespecified subgroups. All P values and 95 percent
confidence intervals were interpreted in a two-tailed
fashion. Statistical significance was designated as
a P value less than 0.05. Stata/SE 8 software was
used for the statistical analysis.
Of the estimated 19,550 persons in the target pop-
ulation in Esturro, 14,164 (72 percent) received a
complete first dose and 11,070 (57 percent) received
two complete doses of the rBS-WC cholera vaccine.
From January 1 to December 31, 2004, 5777 epi-
sodes of acute, nonbloody diarrhea were treated at
the Cholera Treatment Center (Fig. 1); 2599 patients
(45 percent) were admitted, and 20 of them died
(12 adults and 8 children younger than 15 years of
age), for in an in-hospital case fatality rate of 1 per-
cent. None of the case subjects enrolled in the study
died. The first case of laboratory-confirmed cholera
occurred in a resident of a neighborhood other than
Esturro, who presented to the Cholera Treatment
Center on January 12, 2004. Thereafter, cases of
cholera occurred among Esturro residents from
mid-January to mid-April (Fig. 2). Cholera contin-
ued to be detected in the sentinel case subjects from
outside Esturro until May 26, 2004. All cholera iso-
lates were 
 
V. cholerae
 
 O1, El Tor Ogawa.
We compared several baseline characteristics
between the 43 selected case subjects with cholera
and their 172 matched controls and, in the bias-
indicator study, between the 51 case subjects with
noncholeraic diarrhea and their 204 matched con-
trols (Table 1). Case subjects with diarrhea (both
choleraic and noncholeraic) were more likely than
their controls to own multiple kitchen implements
and were less likely to have recently eaten outside
their home. Case subjects with cholera were more
likely than their controls to have recently eaten un-
cooked food and less likely to have recently eaten
dried fish. Case subjects with noncholeraic diarrhea
were less likely than their controls to have electricity
and access to a water tap.
In the primary intention-to-vaccinate analysis,
results
 
* Plus–minus values are means ±SD. 
† Other characteristics, including the number and percentage of participants with a personal history of cholera, a family member with cholera 
in past years, and a family member with diarrhea in the previous week, were not significantly different between case subjects and their 
matched controls.
 
‡ P values are for comparisons between case subjects and their matched controls.
 
Table 1. Characteristics of Case Subjects with Cholera and Case Subjects with Noncholeraic Diarrhea and Their Respective Controls.*
Characteristic† Cholera Noncholeraic Diarrhea
 
Case Subjects
(N=43)
Controls
(N=172)  P Value‡
Case Subjects
(N=51)
Controls
(N=204) P Value‡
Age — yr 19±13 22±17 0.16  28±16 28±16 0.90
Female sex — no./total no. (%) 23/43 (53) 97/172 (56) 0.34 27/51 (53) 108/204 (53) 1.00
Food consumed in previous 5 days — no./total no. (%)
Dairy products 8/42 (19) 39/172 (23) 0.61 3/51 (6) 32/203 (16) 0.07
Uncooked food 25/43 (58) 64/172 (37) 0.01 30/50 (60) 115/203 (57) 0.71
Dried fish 14/43 (33) 93/172 (54) 0.01 16/51 (31) 99/203 (49) 0.69
Street food 0/42 3/172 (2) 0.10 1/51 (2) 2/204 (1) 0.57
Food away from home 37/42 (88) 165/171 (96) 0.04 42/51 (82) 200/204 (98) <0.001
No. of household members 8±15 6±3 0.21 8±13 6±3 0.27
Multiple kitchen implements owned — no./total no. (%) 42/43 (98) 126/172 (73) 0.003 50/51 (98) 140/204 (69) 0.001
Access to a water tap — no./total no. (%) 34/43 (79) 152/172 (88) 0.10 38/51 (75) 189/204 (93) <0.001
Use of a communal toilet — no./total no. (%) 19/43 (44) 63/169 (37) 0.39 18/50 (36) 63/199 (32) 0.29
Electricity in household — no./total no. (%) 7/43 (16) 32/172 (19) 0.64 6/51 (12) 45/204 (22) 0.04
A 
 
machamba
 
 (small farm) owned — no./total no. (%) 16/43 (37) 59/171 (35) 0.71 17/51 (33) 80/203 (39) 0.41
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vaccination was associated with significant protec-
tion (78 percent; 95 percent confidence interval, 39
to 92 percent; P=0.004) against cholera, after ad-
justment for potentially confounding variables (Ta-
ble 2). Because most vaccinees in the intention-to-
vaccinate analysis had received complete two-dose
regimens, the per-protocol analysis indicated a
similar level of protection (84 percent; 95 percent
confidence interval, 43 to 95 percent; P=0.005).
In contrast, there was no evidence that the vaccine
conferred protection against noncholeraic diarrhea
in either the intention-to-vaccinate or per-protocol
analysis.
We performed an intention-to-vaccinate sub-
group analysis of vaccine protection, according to
age at selection and severity of cholera (Table 3). We
found vaccine-associated protection both among
children two to four years of age and among those
five years of age or older. The effectiveness of the
vaccine among those more than 15 years of age —
an age group in which rates of HIV coinfection may
be as high as those among pregnant women in Beira
— was 72 percent (95 percent confidence interval,
24 to 91 percent; P=0.03). Although there was con-
siderable overlap of the confidence limits, the point
estimates were higher for vaccine-associated pro-
tection against cholera accompanied by severe de-
hydration than for protection against disease of
lesser severity (89 percent vs. 73 percent) and were
higher for protection against cholera requiring in-
travenous rehydration than for protection against
that treated only with oral rehydration (82 percent
vs. 75 percent).
Our estimates of the 78 to 84 percent protection
against cholera conferred by the rBS-WC vaccine in
this sub-Saharan setting are nearly identical to the
85 percent protection reported four to six months
after vaccination in previous trials of BS-WC or
rBS-WC vaccines in Bangladesh
 
2,3
 
 and Peru.
 
4
 
 In
agreement with the previous trials, our data suggest
that the rBS-WC vaccine offers better protection
against life-threatening cholera than against chol-
era of lesser severity. However, in contrast to the pre-
vious trials, the current study was conducted in a
population with a high prevalence of coexisting HIV
infection. Moreover, in contrast to the previous tri-
als, which represented idealized evaluations of vac-
discussion
 
* In the case–control study of vaccine effectiveness, case subjects with cholera were compared with controls who did not have diarrhea; in the 
bias-indicator case–control study, case subjects with noncholeraic diarrhea were compared with controls who did not have diarrhea. CI de-
notes confidence interval.
† Odds ratios were adjusted for statistically significant baseline characteristics: consumption of uncooked food, consumption of dried fish, con-
sumption of food away from home, ownership of multiple kitchen implements, access to a water tap, and residence in a household with electricity.
‡ This analysis entailed an assessment of the protection conferred by one or more doses of vaccine against cholera among participants selected 
between January 1 and May 31, 2004.
§ This analysis entailed an asssessment of the protection conferred by two complete doses of vaccine against cholera among vaccinated partic-
ipants selected at least 14 days after receipt of the second dose and nonvaccinated participants selected anytime between January 1 and May 
31, 2004.
¶This analysis entailed an assessment of the protection conferred by one or more doses of vaccine against noncholeraic diarrhea among par-
ticipants enrolled between April 1 and December 31, 2004.
¿ This analysis entailed an assessment of the protection conferred by two complete doses of vaccine against noncholeraic diarrhea among par-
 
ticipants enrolled between April 1 and December 31, 2004.
 
Table 2. Efffectiveness of the Oral Cholera Vaccine in Beira, Mozambique.*
Study and Analysis Vacinees
Crude Odds Ratio
(95% CI)
Adjusted
Odds Ratio
(95% CI)†
Vaccine
Effectiveness
(95% CI)
P
Value
 
Case Subjects Controls
 
no./total no. (%) %
 
Case–control study of vaccine effectiveness
Intention-to-vaccinate analysis‡ 10/43 (23) 94/172 (55) 0.19 (0.08 to 0.54) 0.22 (0.08 to 0.61) 78 (39 to 92) 0.004
Per-protocol analysis§ 8/39 (21) 80/156 (51) 0.17 (0.06 to 0.49) 0.16 (0.05 to 0.57) 84 (43 to 95) 0.005
Bias-indicator case–control study
Intention-to-vaccinate analysis¶ 21/51 (41) 107/204 (52) 0.65 (0.35 to 1.18) 1.00 (0.33 to 3.03) 0 (¡203 to 67) 1.00
Per-protocol analysis¿ 19/51 (37) 101/204 (50) 0.62 (0.33 to 1.15) 1.53 (0.52 to 4.53) ¡53 (¡353 to 48) 0.44
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cine efficacy, the current study was conducted under
the realistic conditions of a public health program
and thus measured the effectiveness of the vac-
cine.
 
17
 
Previous data that support the use of the killed-
whole-cell oral cholera vaccine in sub-Saharan
African settings comes from a study in Ugandan
refugee camps. A two-dose mass immunization
campaign with the rBS-WC vaccine was found to be
feasible in this setting.
 
18
 
 A cholera outbreak oc-
curred in the area the following year, resulting in
cholera attack rates of 1 percent in the nonrefugee
Ugandan villages, less than 1 percent in the 29 non-
vaccinated refugee camps, and 0 percent in the six
vaccinated refugee camps.
 
19
 
 Although the attack
rates suggest that vaccination was protective, the
differences may have been due to varying conditions
in the villages and camps and the geographically
circumscribed nature of cholera outbreaks.
Our study, though not a randomized trial, incor-
porated several features to help ensure the validity
of the results. Prospective surveillance was conduct-
ed in the only treatment facility providing care for
clinically severe, acute, nonbloody diarrhea, and it
is therefore likely that the detection of cases that re-
quired medical care was nearly complete. Patients
underwent systematic microbiologic evaluation, the
results of which were independently validated in an
external laboratory. Histories of vaccination were
prospectively documented, and all decisions about
vaccination status that required linkage to an inde-
pendent registry, rather than inspection of a vacci-
nation card, were made without knowledge of case–
control status. Controls were selected in a matched
fashion, and extensive information about potential-
ly confounding variables was collected and con-
trolled for in the analyses. The analyses, which were
formulated in an a priori fashion, assumed a con-
servative, intention-to-vaccinate perspective. Final-
ly, a bias-indicator case–control study was per-
formed by workers who used procedures identical
to those for the study of vaccine effectiveness and
who were unaware that a separate, bias-indictor
study was being conducted. As expected, this sec-
ond study showed that the vaccine did not provide
protection against noncholeraic diarrhea.
Although our results suggest that the vaccine
offers protection among HIV-infected persons, the
study did not include HIV testing and thus could not
evaluate vaccine protection in that group directly.
For the same reason, the study could not directly as-
sess the safety of the vaccine among HIV-infected
persons, although no clinically significant adverse
reactions to the vaccine were reported during the
 
* This analysis entailed an assessment of protection conferred by one or more doses of vaccine against cholera among 
participants enrolled between January 1 and May 31, 2004. CI denotes confidence interval.
† For this age group, there were no discordant case–control sets, and therefore the stratum was analyzed unmatched and 
exact P values (calculated by Fisher’s exact test) and 95 percent confidence intervals are presented.
‡ The analysis was adjusted for recent consumption of food away from home and for ownership of multiple kitchen imple-
ments.
§ Information about treatment was missing for one case subject, whose controls were therefore also excluded from the 
 
analysis.
 
Table 3. Intention-to-Vaccinate Subgroup Analysis of the Effectiveness of the Oral Cholera Vaccine.*
Variable Vaccinees
Odds Ratio
(95% CI)
Vaccine Effectiveness
(95% CI) P Value
 
Case Subjects Controls
 
no./total no. (%) %
 
Age
2–4 yr † 2/9  (22) 22/36  (61) 0.18 (0.02 to 1.19) 82 (¡19 to 98) 0.04
≥5 yr 8/34 (24) 72/136 (53) 0.33 (0.14 to 0.84) 67 (16 to 86) 0.02
Severity of illness
Severe dehydration 2/10 (20) 24/40  (60) 0.11 (0.01 to 0.93) 89 (7 to 99) 0.04
Some or no dehydration‡ 8/33 (24) 70/132 (53) 0.27 (0.09 to 0.77) 73 (33 to 91) 0.01
Treatment§
Intravenous rehydration‡ 6/29 (21) 63/115 (55) 0.18 (0.05 to 0.65) 82 (35 to 95) 0.009
Oral rehydration 4/13 (31) 28/53  (53) 0.25 (0.05 to 1.37) 75 (¡37 to 95) 0.11
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on February 19, 2014. For personal use only. No other uses without permission. 
 Copyright © 2005 Massachusetts Medical Society. All rights reserved. 
 n engl j med 
 
352;8
 
www.nejm.org february 
 
24
 
, 
 
2005
 
The
 
 new england journal 
 
of
 
 medicine
 
766
 
vaccination campaign. In trials of the rBS-WC vac-
cine in Sweden, Brazil, the United Kingdom, and
Kenya, the vaccine was not associated with adverse
reactions among HIV-infected persons or with pro-
gression of HIV disease, although a transient in-
crease in HIV viremia was observed in one study.
 
20-22
 
Additional research is needed to evaluate directly the
effectiveness of the rBS-WC vaccine among HIV-
infected persons and to clarify the interaction, if any,
between HIV infection and cholera.
The results of this study are very promising and
should encourage policymakers to consider the use
of the rBS-WC oral cholera vaccine as a public health
tool in similar settings, particularly when short-
term protection is crucial, as in the prevention of
cholera outbreaks in refugee settings. More evi-
dence is still needed with respect to long-term pro-
tection before use of this vaccine can be recom-
mended for the control of endemic cholera. It is
uncertain whether the vaccine induces indirect
(“herd”) protection, in addition to direct protec-
tion of vaccinees.
 
23
 
 It will be important for future
studies to evaluate more comprehensively the com-
bined direct and indirect protective effects of the
vaccine when it is deployed in mass-immunization
programs. Finally, the question remains as to how
the costs of acquisition and delivery of the vaccine
can be borne by international donors and by devel-
oping countries with areas at risk for cholera out-
breaks.
In summary, the rBS-WC oral cholera vaccine
was highly effective in conferring short-term pro-
tection against severe cholera in an area of sub-
Saharan Africa with a high prevalence of HIV infec-
tion. This is one step toward the goal of wider use
of oral cholera vaccination where it is needed most.
Many questions remain, including the duration of
protection after mass immunization, financing
schemes for sustainable supply and delivery of the
vaccine, and the potential of the vaccine to control
cholera through combined direct and indirect pro-
tective effects. To help provide answers to the first
two questions, we are continuing the case–control
study throughout the second year after the mass
vaccination and will be assessing the privately and
publicly borne cost of cholera in Beira.
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